Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H10O4 |
Molecular Weight | 242.2268 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OOC(=O)C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=OMPJBNCRMGITSC-UHFFFAOYSA-N
InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H
Molecular Formula | C14H10O4 |
Molecular Weight | 242.2268 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Benzoyl peroxide (BPO) is an organic compound in the peroxide family. It consists of two benzoyl groups bridged by a peroxide link. It is one of the most important organic peroxides in terms of applications and the scale of its production. Benzoyl peroxide is used as an acne treatment, for bleaching hair and teeth. Adverse reactions are: dryness and urticarial reaction, contact dermatitis, application site burning, application site irritation and skin irritation.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
Other AEs: Peeling, Erythema... Other AEs: Peeling (moderate, 55%) Sources: Erythema (moderate, 30%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Erythema | moderate, 30% | 10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
Peeling | moderate, 55% | 10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of certain food additives and contaminants. | 2001 |
|
Oxidative targets in the stratum corneum. A new basis for antioxidative strategies. | 2001 |
|
Syntheses, characterization and application of cross-linked polystyrene-ethyleneglycol acrylate resin (CLPSER) as a novel polymer support for polypeptide syntheses. | 2001 Aug |
|
Effect of benzoyl peroxide on antioxidant status, NF-kappaB activity and interleukin-1alpha gene expression in human keratinocytes. | 2001 Aug 28 |
|
Enzyme-catalyzed decomposition of dibenzoyl peroxide in organic solvents. | 2001 Jul-Aug |
|
The radical-chain addition of aldehydes to alkenes by the use of N-hydroxyphthalimide (NHPI) as a polarity-reversal catalyst. | 2001 Nov 21 |
|
[Optimized polymethyl methacrylate-embedding enables exact section examination of the femur with an uncemented femoral stem]. | 2001 Nov-Dec |
|
Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. | 2001 Sep |
|
Treatment of rosacea. | 2001 Sep |
|
A clinical and therapeutic study of 29 patients with infantile acne. | 2001 Sep |
|
The modern age of acne therapy: a review of current treatment options. | 2001 Sep-Oct |
|
Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. | 2002 |
|
Influence of polymerization conditions on monomer elution and microhardness of autopolymerized polymethyl methacrylate resin. | 2002 Apr |
|
Consideration on the formulation of benzoyl peroxide at ambient temperature: choice of non-polar solvent and preparation of submicron emulsion gels. | 2002 Aug |
|
Low iron state is associated with reduced tumor promotion in a two-stage mouse skin carcinogenesis model. | 2002 Aug |
|
Improving a self-curing dental resin by eliminating oxygen, hydroquinone and water from its curing process. | 2002 Dec |
|
Studies on MMA-tBB resin. I. Comparison of TBB and other initiators in the polymerization of PMMA/MMA resin. | 2002 Dec |
|
Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. | 2002 Feb |
|
The effect of benzoyl peroxide and benzoyl peroxide/erythromycin combination on the antioxidative defence system in papulopustular acne. | 2002 Jan-Feb |
|
Occupational dermatoses among fibreglass-reinforced plastics factory workers. | 2002 Jun |
|
Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes. | 2002 Jun |
|
Oral toxicity of topical preparations. | 2002 Mar |
|
Effect of initiation chemistry on the fracture toughness, fatigue strength, and residual monomer content of a novel high-viscosity, two-solution acrylic bone cement. | 2002 Mar 5 |
|
Clindoxyl gel for the treatment of acne vulgaris. | 2002 May |
|
Allergic contact dermatitis from benzoyl peroxide transferred by a loving son. | 2002 May |
|
Starch-based biodegradable hydrogels with potential biomedical applications as drug delivery systems. | 2002 May |
|
The stability of tretinoin in tretinoin gel microsphere 0.1%. | 2002 Nov |
|
Benzoyl peroxide as a cause of airborne contact dermatitis in an orthopaedic technician. | 2002 Oct |
|
Kinetic evaluation of the reactivity of flavonoids as radical scavengers. | 2002 Oct |
|
Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. | 2002 Sep |
|
Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. | 2002 Sep |
|
Iron augments stage-I and stage-II tumor promotion in murine skin. | 2002 Sep 26 |
|
Topical acne drugs: review of clinical properties, systemic exposure, and safety. | 2003 |
|
Inhibition of benzoyl peroxide and ultraviolet-B radiation induced oxidative stress and tumor promotion markers by cycloartenol in murine skin. | 2003 |
|
Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild-to-moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. | 2003 |
|
Guidelines for the management of acne vulgaris in adolescents. | 2003 |
|
Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. | 2003 Apr |
|
Management of non-neoplastic ovarian cysts with sclerotherapy. | 2003 Apr |
|
Patch testing with the irritant sodium lauryl sulfate (SLS) is useful in interpreting weak reactions to contact allergens as allergic or irritant. | 2003 Feb |
|
Implications of the BEST study. | 2003 Feb |
|
The BEST study: results according to prior treatment. | 2003 Feb |
|
Improving patient satisfaction and acne severity in patients with mild to moderate acne: the BEST study. | 2003 Feb |
|
Determination of organic peroxides by liquid chromatography with on-line post-column ultraviolet irradiation and peroxyoxalate chemiluminescence detection. | 2003 Feb 14 |
|
Management of acne. | 2003 Jan |
|
Topical alpha-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. | 2003 Jan 15 |
|
Progressive iron overload enhances chemically mediated tumor promotion in murine skin. | 2003 Jan 15 |
|
Studies on MMA-TBB resin II. The effect of dual use of TBB and other initiators on polymerization of PMMA/MMA resin. | 2003 Mar |
|
Fox-Fordyce disease. | 2003 Mar |
|
Functionalization of carbon nanotubes by free radicals. | 2003 May 1 |
|
Improved one-pot synthesis of styryl tetrahydrofurans and cyclohexanes by radical addition to beta-nitrostyrenes in the presence of benzoyl peroxide. | 2003 May 9 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Benzamicin gel in combination with adapalene (instead of erythromycin) have to be applied once daily after washing.
Benzamicin gel should be applied twice daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/26806150
The minimum inhibitory concentrations of Benzoyl peroxide were 128 or 256 ug/mL against all isolates of P. acnes
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:52:40 UTC 2023
by
admin
on
Wed Jul 05 22:52:40 UTC 2023
|
Record UNII |
W9WZN9A0GM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
E-928
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.4
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
E-928
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
WHO-ATC |
D10AE01
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
CFR |
21 CFR 333.310
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
EPA PESTICIDE CODE |
128964
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
CFR |
21 CFR 184.1157
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
WHO-VATC |
QD10AE01
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
||
|
WHO-ATC |
D10AE51
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB122302
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
M2389
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | Merck Index | ||
|
W9WZN9A0GM
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
100000085061
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
C47411
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
Benzoyl Peroxide
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
BENZOYL PEROXIDE
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
E-928
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200370
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
372
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
BENZOYL PEROXIDE
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | Description: A white, amorphous or granular powder. Solubility: Practically insoluble in water; soluble in acetone R; soluble in dichloromethane R with separation of water; slightlysoluble in ethanol (~750 g/l) TS. Category: Keratolytic agent. Storage: Hydrous Benzoyl peroxide should be kept in a container that has been treated to reduce static discharge and that has a device for the release of excess pressure. Store at a temperature between 2 and 8 ?C, protected from light. Additional information: CAUTION: Hydrous Benzoyl peroxide may explode at temperatures higher than 60 ?C or if its water content is too low. It may burst into flame in the presence of reducing substances. Unused material must not be returned to the original container but destroyed by treating with sodium hydroxide (~80 g/l) TS to a point where no iodine is liberated after acidifying with hydrochloric acid (~70 g/l) TS and adding a crystal of potassium iodide R. Hydrous Benzoyl peroxide loses water rapidly on exposure to air. It must be handled with care, avoiding contact with the skin and mucous membranes and inhalation of airborne particles. | ||
|
202-327-6
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
7187
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
328
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
W9WZN9A0GM
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
DUAC
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | APPROVED MARCH 2015 | ||
|
SUB11742MIG
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
D001585
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
SUB13020MIG
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
DB09096
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
675
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
DTXSID6024591
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
671
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | |||
|
1418
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY | RxNorm | ||
|
94-36-0
Created by
admin on Wed Jul 05 22:52:40 UTC 2023 , Edited by admin on Wed Jul 05 22:52:40 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|